Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Calculation of postoperative bone healing of cystic lesions of the jaw-a retrospective study.

Sacher C, Holzinger D, Grogger P, Wagner F, Sperl G, Seemann R.

Clin Oral Investig. 2019 Jan 28. doi: 10.1007/s00784-019-02826-y. [Epub ahead of print]

PMID:
30693400
2.

CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells.

Yoon JT, Palazzo AF, Xiao D, Delohery TM, Warburton PE, Bruce JN, Thompson WJ, Sperl G, Whitehead C, Fetter J, Pamukcu R, Gundersen GG, Weinstein IB.

Mol Cancer Ther. 2002 Apr;1(6):393-404.

3.

Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation.

Li H, Liu L, David ML, Whitehead CM, Chen M, Fetter JR, Sperl GJ, Pamukcu R, Thompson WJ.

Biochem Pharmacol. 2002 Nov 1;64(9):1325-36.

PMID:
12392815
4.

Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.

Liu L, Li H, Underwood T, Lloyd M, David M, Sperl G, Pamukcu R, Thompson WJ.

J Pharmacol Exp Ther. 2001 Nov;299(2):583-92.

PMID:
11602670
5.

Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.

Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R.

Cancer Res. 2000 Jul 1;60(13):3338-42.

6.

Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.

Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R, Weinstein IB.

Biochem Pharmacol. 1999 Oct 1;58(7):1097-107.

PMID:
10484067
7.

Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.

Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R.

Cancer Res. 1997 Jul 15;57(14):2909-15.

8.

Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac.

Thompson HJ, Briggs S, Paranka NS, Piazza GA, Brendel K, Gross PH, Sperl GJ, Pamukcu R, Ahnen DJ.

J Natl Cancer Inst. 1995 Aug 16;87(16):1259-60. No abstract available.

PMID:
7563174
9.

Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.

Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R, et al.

Cancer Res. 1995 Jul 15;55(14):3110-6.

10.

Crystallization of a derivative of a new coenzyme, methoxatin.

Forrest HS, Salisbury SA, Sperl G.

Biochim Biophys Acta. 1981 Aug 17;676(2):226-9.

PMID:
7260117
11.

Microbial growth on 2-bromobutane.

Sperl GT, McKae J.

Antonie Van Leeuwenhoek. 1980;46(4):331-41.

12.

In vitro incorporation of molybdate into demolybdoproteins in Escherichia coli.

Scott RH, Sperl GT, DeMoss JA.

J Bacteriol. 1979 Feb;137(2):719-26.

13.

chlD gene function in molybdate activation of nitrate reductase.

Sperl GT, DeMoss JA.

J Bacteriol. 1975 Jun;122(3):1230-8.

14.
15.

Supplemental Content

Support Center